《比较接受体外受精的卵巢储备功能降低患者采用中药预处理的疗效和安全性：一项网络荟萃分析研究方案》
A comparison of the efficacy and safety of traditional Chinese medicine in preconditioning patients with diminished ovarian reserve that would undergo In Vitro fertilization: A network meta-analysis protocol.
机构信息
The First Clinical, Shandong University of Traditional Chinese Medicine.
Rizhao Maternal and Child Health Care Hospital, Rizhao, Shandong Province, China.
出版信息
Medicine (Baltimore). 2021 Jan 29;100(4):e24408. doi: 10.1097/MD.0000000000024408.
BACKGROUND
Diminished Ovarian Reserve (DOR) is a common disease in reproductive-age women in the diagnosis and treatment of infertility. The incidence of DOR increased quickly in recent years and had became one of the most important factors that made the quality of women life decline. Gynecology and reproductive medicine professors have made great efforts to explore good treatment methods all over the world. Traditional Chinese Medicine has made some achievement in treating DOR as a kind of complementary and alternative therapy In Vitro Fertilization (IVF) in recent years, it is indispensable to propose a network meta-analysis (NMA) protocol to discuss the efficacy and safety of TCM in IVF.
METHODS
A literature search will be conducted in 8 electronic databases.
RESULTS
The efficacy and safety of traditional Chinese medicine in preconditioning patients with diminished ovarian reserve that would undergo In Vitro Fertilization will be evaluated.
RESULTS
The systematic review will evaluate the efficacy and safety of TCM in IVF.
CONCLUSION
The result of this study will provide reliable evidence of the use of TCM in IVF.
INPLASY REGISTRATION NUMBER
INPLASY2020110062.
ETHICS AND DISSEMINATION
This review does not require ethical approval.
背景
卵巢储备功能降低（DOR）是生育期妇女不孕诊断和治疗中的常见疾病。近年来，DOR 的发病率迅速上升，已成为导致女性生活质量下降的最重要因素之一。妇科和生殖医学教授们一直在努力探索世界各地的良好治疗方法。近年来，中医药作为体外受精（IVF）的一种补充和替代疗法，在治疗 DOR 方面取得了一些成果，因此有必要提出网络荟萃分析（NMA）方案来讨论中医药在 IVF 中的疗效和安全性。
方法
将在 8 个电子数据库中进行文献检索。
结果
将评估中医药在接受体外受精的卵巢储备功能降低患者预处理中的疗效和安全性。
结果
系统评价将评估中医药在 IVF 中的疗效和安全性。
结论
这项研究的结果将为中医药在 IVF 中的应用提供可靠的证据。
INPLASY 注册号：INPLASY2020110062。
伦理与传播
本综述不需要伦理批准。
Zotero 插件